These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 33175958)

  • 1. Hypogammaglobulinemia after rituximab for rheumatoid arthritis is not rare and is related with good response: 13 years real-life experience.
    Evangelatos G; Fragoulis GE; Klavdianou K; Moschopoulou M; Vassilopoulos D; Iliopoulos A
    Rheumatology (Oxford); 2021 May; 60(5):2375-2382. PubMed ID: 33175958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases.
    Md Yusof MY; Vital EM; McElvenny DM; Hensor EMA; Das S; Dass S; Rawstron AC; Buch MH; Emery P; Savic S
    Arthritis Rheumatol; 2019 Nov; 71(11):1812-1823. PubMed ID: 31131994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: A 12-year longitudinal multi-center study.
    Boleto G; Avouac J; Wipff J; Forien M; Dougados M; Roux C; Kahan A; Dieude P; Allanore Y
    Semin Arthritis Rheum; 2018 Oct; 48(2):149-154. PubMed ID: 29548542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab-associated hypogammaglobulinemia in autoimmune rheumatic diseases: a single-center retrospective cohort study.
    Wade SD; Kyttaris VC
    Rheumatol Int; 2021 Jun; 41(6):1115-1124. PubMed ID: 33811499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world effectiveness and safety of rituximab in the treatment of rheumatoid arthritis: A single-center experience in Taiwan.
    Wang KC; Liao HT; Chen WS; Lai CC; Chou CT; Chen MH; Tsai CY
    Int J Rheum Dis; 2019 May; 22(5):860-868. PubMed ID: 30761753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low immunoglobulin levels increase the risk of severe hypogammaglobulinemia in granulomatosis with polyangiitis patients receiving rituximab.
    Besada E
    BMC Musculoskelet Disord; 2016 Jan; 17():6. PubMed ID: 26738559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies.
    Einarsson JT; Evert M; Geborek P; Saxne T; Lundgren M; Kapetanovic MC
    Clin Rheumatol; 2017 Dec; 36(12):2743-2750. PubMed ID: 28980088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypogammaglobulinemia and Infection Events in Patients with Autoimmune Diseases Treated with Rituximab: 10 Years Real-Life Experience.
    Nie Y; Zhang N; Li J; Wu D; Yang Y; Zhang L; Bai W; Jiang N; Qiao L; Huang C; Zhou S; Tian X; Li M; Zeng X; Peng L; Zhang W
    J Clin Immunol; 2024 Aug; 44(8):179. PubMed ID: 39150626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-life drug retention rate and safety of rituximab when treating rheumatic diseases: a single-centre Swiss retrospective cohort study.
    Dumusc A; Alromaih F; Perreau M; Hügle T; Zufferey P; Dan D
    Arthritis Res Ther; 2023 Jun; 25(1):91. PubMed ID: 37264414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline serum immunoglobulin levels in patients with rheumatoid arthritis: relationships with clinical parameters and with B-cell dynamics following rituximab.
    de la Torre I; Leandro MJ; Edwards JC; Cambridge G
    Clin Exp Rheumatol; 2012; 30(4):554-60. PubMed ID: 22510323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study.
    Varisco V; Viganò M; Batticciotto A; Lampertico P; Marchesoni A; Gibertini P; Pellerito R; Rovera G; Caporali R; Todoerti M; Covelli M; Notarnicola A; Atzeni F; Sarzi-Puttini P
    J Rheumatol; 2016 May; 43(5):869-74. PubMed ID: 26879359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease.
    Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR
    J Autoimmun; 2015 Feb; 57():60-5. PubMed ID: 25556904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritis.
    Lindenberg L; Spengler L; Bang H; Dorner T; Maslyanskiy AL; Lapin SV; Ilivanova EI; Martinez-Gamboa L; Bastian H; Wittenborn E; Egerer K; Burmester GR; Feist E
    Arthritis Res Ther; 2015 Aug; 17(1):206. PubMed ID: 26268352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial.
    Smolen JS; Cohen SB; Tony HP; Scheinberg M; Kivitz A; Balanescu A; Gomez-Reino J; Cen L; Poetzl J; Shisha T; Kollins D
    Rheumatology (Oxford); 2021 Jan; 60(1):256-262. PubMed ID: 32699904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases.
    Khojah AM; Miller ML; Klein-Gitelman MS; Curran ML; Hans V; Pachman LM; Fuleihan RL
    Pediatr Rheumatol Online J; 2019 Aug; 17(1):61. PubMed ID: 31462263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Incidence of hypogammaglobulinaemia in children with steroid-dependent/frequently relapsing nephrotic syndrome treated with rituximab and its association with severe infections].
    Zhi YZ; Cao L; Ying DJ; Dou WJ; Gu R; Zhang JJ
    Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(6):433-439. PubMed ID: 38326055
    [No Abstract]   [Full Text] [Related]  

  • 17. Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN survey.
    Zurowska A; Drozynska-Duklas M; Topaloglu R; Bouts A; Boyer O; Shenoy M; Vivarelli M;
    Pediatr Nephrol; 2023 Sep; 38(9):3035-3042. PubMed ID: 37014530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety profile of repeated rituximab cycles in unselected rheumatoid arthritis patients: a long-term, prospective real-life study.
    Vassilopoulos D; Delicha EM; Settas L; Andrianakos A; Aslanidis S; Boura P; Katsounaros M; Athanassiou P; Tempos K; Skarantavos G; Antoniadis C; Papazoglou S; Sakkas L; Galanopoulou V; Skopouli F; Boki K; Daoussis D; Vritzali E; Sfikakis PP
    Clin Exp Rheumatol; 2016; 34(5):893-900. PubMed ID: 27383049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infection incidence, timing and dose dependency in rheumatoid arthritis patients treated with rituximab: a retrospective cohort study.
    Veeken LD; Opdam MAA; Verhoef LM; Popa C; van Crevel R; den Broeder AA
    Rheumatology (Oxford); 2024 May; 63(5):1246-1250. PubMed ID: 37410085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry.
    Gottenberg JE; Ravaud P; Bardin T; Cacoub P; Cantagrel A; Combe B; Dougados M; Flipo RM; Godeau B; Guillevin L; Le Loët X; Hachulla E; Schaeverbeke T; Sibilia J; Baron G; Mariette X;
    Arthritis Rheum; 2010 Sep; 62(9):2625-32. PubMed ID: 20506353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.